Morgan Stanley has upgraded PTC Therapeutics (PTCT), while downgrading Immuneering (IMRX) and Amicus Therapeutics (FOLD).

Morgan Stanley kept Apple as its "Top Pick" for 2025 as the bank sees the tech giant's artificial intelligence (AI) product ...

The stock's fall snapped a two-day winning streak.

Sempra (NYSE:SRE) +1.5% in Friday's trading as Morgan Stanley upgrades to Overweight from Equal Weight with a $98 price ...

Morgan Stanley is close to an agreement to buy around €900 million ($940 million) in Spanish mortgages from Banco Santander ...

Import prices edged up 0.1% last month after a downwardly revised 0.1% rise in October, the Labor Department's Bureau of ...

Joby Aviation's strategic investments and cash reserves, despite recent stock price volatility, position the company for ...

Investors and traders in the stock market love to ride momentum, and the build-out of data processing infrastructure to ...

After back-to-back years of more than 20% returns for the S&P 500, what's in store for 2025? Most on Wall Street say more ...

Shares of Broadcom popped more than 21% Friday, pushing the company’s market cap beyond $1 trillion for the first time.

The struggling $8 bln drugstore is buried under a $36 billion morass of debt, leases and legal costs. Yet, a carefully ...

Morgan Stanley analyst Bob Huang notes that Progressive November results showed strong underwriting improvements, alleviating the fear of adverse selection, seasonal trends, and l ...